1. Home
  2. SPOK vs IKT Comparison

SPOK vs IKT Comparison

Compare SPOK & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spok Holdings Inc.

SPOK

Spok Holdings Inc.

HOLD

Current Price

$11.14

Market Cap

230.7M

ML Signal

HOLD

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

HOLD

Current Price

$1.74

Market Cap

240.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPOK
IKT
Founded
2004
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
230.7M
240.1M
IPO Year
2004
2020

Fundamental Metrics

Financial Performance
Metric
SPOK
IKT
Price
$11.14
$1.74
Analyst Decision
Hold
Strong Buy
Analyst Count
1
5
Target Price
$14.00
$5.00
AVG Volume (30 Days)
158.7K
1.2M
Earning Date
04-29-2026
03-26-2026
Dividend Yield
11.26%
N/A
EPS Growth
2.74
57.76
EPS
0.75
N/A
Revenue
$139,708,000.00
N/A
Revenue This Year
$1.70
N/A
Revenue Next Year
N/A
$33.33
P/E Ratio
$14.80
N/A
Revenue Growth
1.49
N/A
52 Week Low
$10.81
$1.33
52 Week High
$19.31
$2.37

Technical Indicators

Market Signals
Indicator
SPOK
IKT
Relative Strength Index (RSI) 37.52 46.81
Support Level N/A $1.43
Resistance Level $13.87 $1.74
Average True Range (ATR) 0.26 0.12
MACD 0.05 -0.00
Stochastic Oscillator 52.31 35.87

Price Performance

Historical Comparison
SPOK
IKT

About SPOK Spok Holdings Inc.

Spok Holdings Inc is a provider of healthcare communications. The company delivers clinical communication and collaboration solutions to help protect the health, well-being, and safety of people in the United States and abroad, on a limited basis, in Europe, Canada, Australia, Asia, and the Middle East. The company develops, sells, and supports enterprise-wide systems principally for healthcare and other organizations needing to automate, centralize, and standardize their approach to clinical and critical communications. The company offers its services and products to three market segments: healthcare, government, and large enterprise, with a greater emphasis on the healthcare market segment. Geographically, the company generates the majority of its revenue from the United States.

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.

Share on Social Networks: